Month: April 2021

RIDGEFIELD, Conn., April 28, 2021 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States and Canada, today reported financial results for its first quarter ended March 26, 2021. Financial highlights for the first quarter of 2021:Net sales decreased 25.4% to $280.2 million for the first quarter of 2021 from $375.4 million for the first quarter of 2020. GAAP net loss was $17.9 million, or $(0.49) per diluted share, for the first quarter of 2021 compared to net loss of $14.1 million, or $(0.48) per diluted share, in the first quarter of 2020. Adjusted EPS1 was $(0.50) for the first quarter of 2021 compared to $(0.60) for the first quarter of 2020. Adjusted EBITDA1 was $(9.5) million for the first quarter of 2021 compared to $(13.8)...

SAN FRANCISCO, April 28, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021 at 5:00 PM Eastern Time. A live audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days. About FibroGen FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently...

TORONTO, April 28, 2021 (GLOBE NEWSWIRE) — Stone Gold Inc. (TSX-V: STG) (“Stone Gold” or the “Company“) announces the appointment of Birks Bovaird to its Board of Directors. Mr. Bovaird is a Consultant, providing advisory services to natural resource companies. For the majority of his career, Mr. Bovaird’s focus has been the provision and implementation of corporate financial consulting and strategic planning services. After spending over two decades with various financial institutions, culminating in the role of Managing Director of the Canadian operations of an international bank, he took on the role of Vice President of Corporate Finance for one of Canada’s major accounting firms.  Mr. Bovaird has previously been involved with numerous public resource and non-resource companies, both as a member...

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that final results from the CANTATA clinical study will be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting taking place virtually June 4-8, 2021. Earlier this year, Calithera announced topline results from the Phase 2 CANTATA trial, which evaluated the efficacy and safety of the company’s glutaminase inhibitor, telaglenastat, in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic renal cell carcinoma (RCC) who had been treated with one or...

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) — Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27. “Ian is a proven biotechnology leader with a diverse skill set, and I am excited to welcome him to our Board at this important time in the company’s evolution,” stated Adrian Gottschalk, Foghorn’s Chief Executive Officer. “Ian has been advising the company since early 2020 on various initiatives including business development and equity financing strategies as well as company progression and development. The addition of Ian to our Board brings significant business experience and capital...

Reported potent interim immunogenicity results for anti-pTau Alzheimer’s vaccine in ongoing Phase 1b/2a study, which support further development into Phase 2/3 Initiated first-in-human clinical study for next-generation alpha-synuclein PET diagnostic with results expected in Q3 2021 Advanced multiple candidates targeting the NLRP3 inflammasome pathway for CNS and non-CNS indications Strong financial position of CHF 216.1 million in cash ensures the Company is fully financed through at least Q1 2024LAUSANNE, Switzerland, April 28, 2021 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2021. The Company also provided an overview of its recent clinical and corporate...

TTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including 3 new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure; TTI-621 monotherapy shows 18-29% ORR in R/R T- and B-cell lymphomas at 0.2-2.0 mg/kg doses, including 3 new responses (1 CR + 2 PRs) in cutaneous T-cell lymphoma (CTCL) since last data disclosure; TTI-622 and TTI-621 have been well tolerated at doses up to 18 mg/kg and 2.0 mg/kg weekly, respectively; neither drug candidate reached a maximum tolerated dose (MTD) level; Phase 1b/2 program across seven hematologic and solid tumor indications has been initiated, with studies across nine patient settings to start over approximately the next twelve months; Scott Myers joins the Board of Directors; Robert Kirkman and...

NEW YORK, and RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) — Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced four upcoming oral presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually between May 11th to May 14th, 2021. The AXO-AAV-GM1 presentation will include a review of patient-level data on safety and efficacy at 6 months follow up from the low-dose cohort of the Company’s ongoing clinical study. Additionally, Dr. Cynthia Tifft, the lead investigator for the study, will present 6-month biomarker data from cerebrospinal fluid (CSF) in the 5 children who received intravenous AAV9 gene therapy. Oral...

Great Place to Work® Certification in the United Kingdom, Spain, Italy and Germany PHILADELPHIA, April 28, 2021 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been recognized by the prestigious Great Place to Work® Institute as among the best places to work in the United Kingdom, Spain, Italy and Germany. The company has also been recognized with a Best Workplaces Bavaria designation. Great Place to Work® is an international research and consulting institute that supports organizations in developing their corporate and workplace culture. This certification indicates that an organization’s workplace culture is validated through anonymous employee feedback, based...

SANTA MONICA, Calif., April 28, 2021 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and, pending closing of the announced transaction with NeurMedix, neurological and neuro-degenerative disorders and certain cancers, today announced the participation of its President and Chief Executive Officer Cuong Do at the 2021 B. Riley Securities’ Neuroscience Conference. Mr. Do is scheduled to present on Wednesday, April 28 at 3:00 PM Eastern Time and will discuss BioVie’s pending acquisition of NeurMedix’s assets and plans going forward for Alzheimer’s and Parkinson’s. BioVie Presentation Details Date: Wednesday, April 28, 2021 Time: 3:00 PM Eastern Time A live webcast of BioVie’s presentation...